Medical Treatment for Diamond Blackfan Anemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

1998-07-31

Study Completion Date

2005-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Diamond Blackfan anemia (DBA) is a condition in which the bone marrow is underdeveloped. DBA is considered a congenital disease, meaning patients are born with it. In DBA there is a lack of cells that give rise to red blood cells. The other elements produced in the bone marrow, such as white blood cells and platelets, are normal.

Standard treatments used for this disorder such as steroids and bone marrow transplants are associated with failure, relapse, side-effects, increased morbidity, and even death. Two drugs, antithymocyte globulin (ATG) and cyclosporin have been used to treat DBA, but have only provided occasional responses. No study has ever combined these two drugs for the treatment of DBA.

This study is designed to explore the combined use of ATG and cyclosporine as a rational approach to the treatment of DBA.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag

NCT04269889

Anemia, Diamond-Blackfan

COMPLETED PHASE1/PHASE2

Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia

NCT01362595

Diamond Blackfan Anemia Blackfan Diamond Syndrome DBA +2 more

COMPLETED PHASE1/PHASE2

L-leucine in Diamond Blackfan Anemia Patients

NCT02386267

Diamond Blackfan Anemia

UNKNOWN PHASE2

Diamond Blackfan Anemia Registry (DBAR)

NCT00106015

Anemia Blood Disease

RECRUITING

Eltrombopag for People With Fanconi Anemia

NCT03206086

Fanconi Anemia

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Diamond Blackfan anemia (DBA) is a constitutional pure red cell aplasia of unknown etiology. There is laboratory evidence for an immune mechanism and most patients respond to corticosteroids. However the relapse and failure rate are high, and corticosteroids are associated with many short and long term side effects. Patients who do not respond or who do not tolerate corticosteriods require lifelong red blood cell transfusion and iron chelation therapy. Allogeneic bone marrow transplantation is an option for those with a related histocompatible donor, but this procedure is associated with high mortality and morbidity. Other therapies have been tried without general success. Occasional responses to either ATG or cyclosporine have been reported, but no study has used both ATG and cyclosporine. In other blood/bone marrow disorders of immune etiology these drugs have synergistic effects. We propose a Phase II study to explore the combined use of ATG and cyclosporine as a rational approach to the treatment of Diamond Blackfan anemia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fanconi's Anemia Hematologic Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Antithymocyte globulin

Intervention Type DRUG

Cyclosporine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Diagnosis of DBA as characterized by a hyporegenerative anemia presenting in early childhood with reticulocytopenia, and low or absent erythroid precursors in the bone marrow.

Transfusion-dependence due to steroid failure or intolerance of steroid side effects.

Ineligible for or declining an allogeneic transplant.

Ages 3 to 75.

Exclusion Criteria

Serum creatinine greater than 2 times normal or a creatinine clearance less than 50% normal.

SGPT or SGOT greater than 5 times normal.

History of epilepsy (any seizures besides childhood febrile seizures).

Current pregnancy or unwillingness to take oral contraceptives if menstruating.

Positive diepoxybutane (DEB) test for Fanconi anemia.

HIV positivity.

Inability or unwillingness to sign an informed consent, either by the patient, or in the case of a minor, by the parent or guardian responsible for the patient.

Underlying organ failure and/or those with a Karnofsky performance status of less than 1.

Treatment with androgens, prednisone greater than 10 mg/day, growth factors, or other immunosuppressive therapies within one month of protocol entry.

Ongoing treatment with Beta-adrenergic blocking drugs.

Previous treatment with ATG and concurrent CSA. Previous treatment with either drug alone is acceptable if greater than one year prior to study entry.

Eligible Sex

ALL

Accepts Healthy Volunteers

No